市場調查報告書

罕見疾病診斷的全球市場 - 分析、預測:遺傳病、服務供應商、競爭情形 (2018-2023年)

Global Rare Disease Diagnostics Market: Focus on Genetic Diseases, Service Providers, Competitive Landscape, and Country - Analysis and Forecast, 2018-2025

出版商 BIS Research Inc. 商品編碼 740506
出版日期 內容資訊 英文 244 Pages
商品交期: 最快1-2個工作天內
價格
罕見疾病診斷的全球市場 - 分析、預測:遺傳病、服務供應商、競爭情形 (2018-2023年) Global Rare Disease Diagnostics Market: Focus on Genetic Diseases, Service Providers, Competitive Landscape, and Country - Analysis and Forecast, 2018-2025
出版日期: 2018年10月31日內容資訊: 英文 244 Pages
簡介

全球罕見疾病診斷的市場規模,預測至2025年將達到861億5,000萬美元的規模。各國按照其人口定義罕見疾病。因為當初製藥公司對這樣小規模的患者族群的治療藥開發沒有太大興趣,美國FDA (食品藥物管理局) 開始指定罕見疾病的治療藥候補孤兒藥 (罕見疾病用醫藥品)。罕見疾病治療的大課題,為診斷的不足,政府的政策,R&D的認識和資金,及診斷大幅度的遲滯等。

本報告提供全球罕見疾病診斷的市場調查,市場概要,市場成長的各種影響因素分析,競爭環境,各市場區隔、各地區的趨勢與市場規模的變化與預測,主要製造商的簡介等資料彙整。

第1章 市場概要

第2章 市場動態

  • 市場動態:促進因素、阻礙因素、機會、課題
  • 促進因素
  • 課題
  • 機會
  • 趨勢

第3章 競爭情形

  • 產品銷售
  • 合資企業、合作、聯盟
  • 罕見疾病研究的進步
  • 服務供應商

第4章 產業考察

  • 資金情形
  • 法律上的必要條件、規定
  • 法規團體的清單

第5章 全球罕見疾病診斷市場:各疾病類型

  • 要點
  • 罕見疾病市場魅力:各疾病類型
  • 概要:各疾病類型
  • 市場概要:各疾病類型
  • 市值:消化器官疾病
  • 市值:內分泌、代謝疾病
  • 市值:心血管疾病
  • 市值:血液、癌症疾病
  • 市值:皮膚疾病
  • 市值:其他治療領域

第6章 全球罕見疾病診斷市場:各檢驗類型

  • 要點
  • 罕見疾病市場魅力:各檢驗類型
  • 概要:各檢驗類型
  • 市場概要:各檢驗類型
  • 市值:遺傳基因檢驗
  • 市值:一般檢驗
  • 市值:影像檢查
  • 市值:其他檢驗

第7章 全球罕見疾病診斷市場:各特徵

  • 要點
  • 罕見疾病市場魅力:各特徵
  • 概要:各特徵
  • 市場概要:各特徵
  • 市值:遺傳性
  • 市值:後天性

第8章 全球罕見疾病診斷市場:各年齡層

  • 要點
  • 罕見疾病市場魅力:各年齡層
  • 概要:各年齡層
  • 市場概要:各年齡層
  • 市值:兒童
  • 市值:成人

第9章 全球罕見疾病診斷市場:各終端用戶

  • 要點
  • 罕見疾病市場魅力:各終端用戶
  • 市場概要:各終端用戶
  • 市值:醫院實驗室
  • 市值:診斷實驗室
  • 市值:遺傳基因檢驗實驗室
  • 市值:癌症研究實驗室
  • 市值:其他終端用戶

第10章 全球罕見疾病診斷市場:各地區

  • 市場概要:各地區
  • 全球市場:各地區
  • 市值:各地區

第11章 北美的罕見疾病診斷市場

  • 市場概要:各國
  • 市場促進成長要素與阻礙因素的影響
  • 市值:各國
  • 市值:美國
  • 市值:加拿大

第12章 歐洲

  • 市場概要:各國
  • 市場促進成長要素與阻礙因素的影響
  • 市值:各國
  • 市值:英國
  • 市值:德國
  • 市值:法國
  • 市值:俄羅斯
  • 市值:義大利
  • 市值:西班牙
  • 市值:其他

第13章 南美

  • 市場概要:各國
  • 市場促進成長要素與阻礙因素的影響
  • 市值:各國
  • 市值:巴西
  • 市值:墨西哥
  • 市值:其他

第14章 亞太地區

  • 市場概要:各國
  • 市場促進成長要素與阻礙因素的影響
  • 市值:各國
  • 市值:中國
  • 市值:日本
  • 市值:印度
  • 市值:澳洲
  • 市值:新加坡
  • 市值:其他

第15章 MEA (中東、非洲)

  • 市場概要:各國
  • 市場促進成長要素與阻礙因素的影響
  • 市值:各國
  • 市值:GCC各國
  • 市值:南非
  • 市值:其他

第16章 企業簡介

  • 23andMe, Inc.
  • 3billion, Inc.
  • BGI
  • Centogene A.G.
  • Eurofins Scientific
  • GENEWIZ
  • Illumina Inc.
  • InDepth Genomics
  • Laboratory Corporation of America
  • Partek, Inc.
  • PerkinElmer, Inc.
  • Personal Genome Diagnostics, Inc.
  • QIAGEN N.V.
  • Retrophin, Inc.
  • Strand Life Sciences Pvt Ltd.
目錄
Product Code: BH071A

Global Rare Disease Diagnostics Market to Reach $86.15 billion by 2025, Reports BIS Research

Rare diseases, also known as orphan diseases, have become a major health burden in the recent times. Comprising 6000-7000 life threatening diseases, rare diseases affect small percentage of the population. Every country has their own definition of rare disease based on the country's population. In the initial years, pharmaceutical companies were less interested in adopting them to develop treatments for such a small patient population, therefore the US FDA started giving orphan drug designations to the drug candidates intended to treat rare diseases. Orphan drug designations benefit companies from incentives for the development of these products until the marketing approval. The major challenge in rare diseases treatment is the lack of diagnosis, government policies, awareness and funding for R&D, along with long diagnostic delays.

The increasing patient pool for rare disease cancer, government funding to accelerate research in rare diseases, and interest of big pharmaceutical companies in manufacturing orphan drugs and orphan disease diagnostic devices are expected to be the major factors for the growth of the market. Pharmaceutical giants such as Shire and Qiagen are investing in the R&D for the development of innovative and improved diagnostic devices and assays for rare disease. Rise in the awareness level among people on rare diseases is also expected to fuel the growth of the market. The rare disease has different definitions across different countries. Rare diseases are genetically inherited and is difficult and expensive to diagnose and with are few treatment options. A disease is known as rare in the United States if it affects fewer to 200,000 people, and in Europe, a disease is referred to as rare if it affects one in 2000 people. Rare diseases are also referred to those diseases that are underappreciated or ignored by the medical community and drug companies

The global rare disease diagnostic market is segmented based on disease type, test type, age, trait, end-user, and region. The disease type segment is further sub-segmented into gastroenterology, endocrine and metabolism disorders, cardiovascular disorders, neurology, hematology and oncology, dermatology, and other therapeutic areas. The test type segment is further segmented as genetic tests, general lab tests, imaging, and other physical tests for rare diseases. On the basis of trait type, the rare disease diagnostic market is segmented as inherited and acquired. Based on the age group, the rare disease diagnostic market is segmented into children and adults. On the basis of end user, the rare disease diagnostic marker is segmented as hospital laboratories, diagnostic laboratory, genetic testing laboratories, cancer research laboratories, and others genetic services area. The market analysis includes an in-depth examination of the key ecosystem players, key strategies, and developments taking place in this market. Additionally, it includes market dynamics (market drivers, opportunities, and challenges) and industry analysis. Geographically, the market can be segmented into five distinct regions including, North America, Europe, Asia-Pacific, Latin America, and Middle East Africa (MEA).

The purpose of the study is to gain a holistic view of the global rare disease diagnostic market in terms of various factors influencing it such as key market trends, competitive and regulatory aspects of the market, and scientific innovations with respect to gene sequencing. The scope of the report is centered upon conducting a detailed study of the diagnostic devices/services and assays used to diagnose rare disease. It involves wide range of diagnostic tests such as genetic tests (genome sequencing and exome sequencing), lab tests, imaging, and physical examinations that are performed in diagnostic laboratories, hospitals, cancer research institutes and other gene sequencing institutes/companies.

The rare disease diagnostic market is divided into six different segments: diseases, test type, 'trait, age, end user, and region. The report offers the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering the market.

This research report aims at answering questions related to various aspects of the global market with the help of the key factors driving the market, threats that can possibly inhibit the overall market growth, and the current growth opportunities that are going to shape the future trajectory of the market expansion. The study considers the growth-share matrix model for a comprehensive study of the global enzyme market, and assesses the factors governing the same. Opportunity matrix and detailed product mapping have been included in the report. The market by region has been further sub-segmented in various countries, and in each sub-segment the key market trends, list of the key players, and recent developments, have been discussed.

Key questions answered in the report:

  • What are the major market drivers, restraints, and opportunities in the global rare disease diagnostic market?
  • What were the market shares of the leading segments and sub-segments of the global rare disease diagnostic market in 2017, and what will be shares in 2025?
  • How will each segment of the global rare disease diagnostic market grow during the forecast period, and what will be the revenue generated by each of the segments by the end of 2025?
  • What are the influencing factors that may affect the market share of the key players?
  • What are the key developmental strategies implemented by the key players to stand out in this market?
  • What are the major regulatory authorities/associations/consortiums affecting the global rare disease diagnostic market, and who are the key authorities facilitating development and approval of diagnostic products/services?
  • Which companies are holding gene sequencing services, and what is the epidemiology of the rare diseases?
  • What are the types of genetic tests involved in the diagnosis of rare diseases, and what is the market share for various test types performed in the diagnosis of rare diseases?
  • Which test type will be dominant among physicians for diagnosing rare diseases in terms of revenue?
  • Which disease type is expected to have the highest CAGR during the forecast period?
  • Which test type is expected to register the highest CAGR for the global rare disease diagnostic market?
  • Which end user is expected to register the highest CAGR for the global rare disease diagnostic market?
  • Which geographical region will contribute to the highest revenue for rare disease diagnosis during the forecast period?

The report also profiles 15 companies including several key players that have been contributing significantly to the market. They key players of the market include Retrophin, Inc., 3billion, Inc., 23andMe, Inc., QIAGEN N.V., Illumina Inc., PerkinElmer, Inc., BGI, Partek, Inc., GENEWIZ, Centogene A.G., Strand Life Sciences Pvt Ltd., Eurofins Scientific, Laboratory Corporation of America, and Laboratory Corporation of America, among others.

Executive Summary

Rare diseases have become a major health burden in the recent times. Also known as orphan diseases, rare diseases are a group of 6000-7000 life threatening diseases affecting a small percentage of the population. Countries also have their own definition of rare disease based on the population. Rare diseases are also known as orphan diseases because pharmaceutical companies were less interested in adopting them to develop treatments for small patient population. The US FDA then decided to design drugs as orphan drugs and give incentives to encourage companies to develop diagnostics and treatment options for rare diseases. The major challenge in the case of rare diseases is the lack of diagnosis and treatment options, government policies, and funding for research and development.

The global rare disease diagnostics market was valued $45.18 billion in 2017 and is anticipated to reach $86.15 billion by 2025. Factors such as high incidence of rare diseases, presence of large numbers of research and development facilities for rare diseases, significant number of rare disease registries, high diagnosis rare of rare diseases in countries of North America, and extensive investments in different therapeutic areas are driving the growth of the North America rare disease diagnostics market. However, the Asia Pacific region is expected to register the highest CAGR of 9.22% during the forecast period 2018-2025.

The purpose of the study is to gain a holistic view of the global rare disease diagnostics market in terms of various factors influencing it such as key market trends, competitive and regulatory aspects of the market, and scientific innovations with respect to gene sequencing. The scope of the report is centered upon conducting a detailed study of the diagnostic devices/services, assays used to diagnose rare diseases. Rare disease diagnosis involves wide range of diagnostic tests such as genetic tests, lab tests, imaging, physical examinations performed in diagnostic laboratories, hospitals, cancer research institutes and others. The rare disease diagnostics market is divided into six different segments: diseases, test type, trait, age, end user, and region. The report offers the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well-informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering the market.

The global rare disease diagnostics market (by disease type) is currently dominated by hematology and oncology segment. The contribution of hematology and oncology segment was valued $10.0 billion in 2017 and is expected to reach $20.5 billion by 2025, witnessing a CAGR of 9.35% during the forecast period.

Based on test type, the market is segmented into genetic tests, general lab tests, imaging, and other physical tests for rare diseases. Rare diseases are difficult to diagnose and according to NIH, as many as 80 % of rare diseases are genetic in origin, thus often requiring genetic test for diagnosis

Based on the trait type, the market is segmented into inherited and acquired. Based on the age group, the market is segmented into children and adults. About 80% of rare diseases are not acquired, they are inherited or has predisposition of faulty gene. The average time to diagnosis is approximately 5-6 years and 40% of rare diseases are misdiagnosed. Children account for 50 % of rare disease patients. According to the Canadian Organization of Rare Diseases, two-third of Canadians suffering from rare disease are children. Another extremely unfortunate fact is that thirty percent of children with rare diseases are not likely to reach their fifth birthday.

Geographically, the market is segmented into five distinct regions including North America, Europe, Asia-Pacific, Latin America, and Middle East Africa (MEA). North America, followed by Europe, is the leading contributor of the market. Within North America, the U.S. contributed for almost 91.12% of the total share, and the rest was occupied by Canada in 2017. Within Europe, the U.K dominated the market in 2017. However, the market for the Asia-pacific region is expected to demonstrate high growth rate during the forecast period from 2018 to 2025, as compared to other regions, and the region holds a strong potential for market expansion in the future.

The rare disease diagnostics market (by genetic tests) has a promising potential for growth in the coming years. The report provides an in-depth SWOT analysis of different key players of the market, supported by extensive financial summary of each company. The key players of the market include Retrophin, Inc., QIAGEN N.V., Illumina Inc., PerkinElmer, Inc., BGI, Partek, Inc., Centogene A.G., Strand Life Sciences Pvt Ltd., Eurofins Scientific, Laboratory Corporation of America, and Laboratory Corporation of America, among others.

Table of Contents

Executive Summary

1 Market Overview

  • 1.1 Rare Disease Introduction
  • 1.2 Tests Performed during Diagnosis
  • 1.3 Rare Disease Challenges and Recommendations
  • 1.4 List of Genetic Tests
  • 1.5 Rare Disease Policies
  • 1.6 A Path to Success: Partnerships and Coordinated Efforts of the Rare Diseases Community
  • 1.7 Global Market Overview
  • 1.8 Assumptions and Limitations

2 Market Dynamics

  • 2.1 Market Dynamics: Drivers, Restraints, and Opportunities, and Trends
  • 2.2 Rare Disease Diagnostics Market: Drivers
  • 2.3 Rare Disease Diagnostics Market: Challenges
  • 2.4 Rare Disease Diagnostics Market: Opportunity
  • 2.5 Rare Disease Diagnostics Market: Trends

3 Competitive Landscape

  • 3.1 Product Launches
  • 3.2 Joint Venture, Collaborations, and Partnerships
  • 3.3 IRDiRC Perspective: Progress in Rare Diseases Research, 2010-2016
  • 3.4 Service Providers

4 Industry Insights

  • 4.1 Funding Scenario
  • 4.2 Legal Requirements and Regulations
  • 4.3 List of Regulatory Bodies

5 Global Rare Disease Diagnostics Market (by Disease Type)

  • 5.1 Key Takeaways
  • 5.2 Rare Disease Market Attractiveness (by Disease Type)
  • 5.3 Overview: Disease Type
  • 5.4 Market Overview: Disease Type
  • 5.5 Market Value (by Gastroenterology Disease Type), 2017-2025
  • 5.6 Market Value ((by Endocrine and Metabolism Disorders Disease Type)), 2017-2025
  • 5.7 Market Value (by Cardiovascular Disorders), 2017-2025
  • 5.8 Market Value (by Neurology Disease Type), 2017-2025
  • 5.9 Market Value (by Hematology and Oncology Disease Type), 2017-2025
  • 5.10 Market Value (by Dermatology Disease Type), 2017-2025
  • 5.11 Market Value (by Other Therapeutic Areas), 2017-2025

6 Global Rare Disease Diagnostics Market (by Test Type)

  • 6.1 Key Takeaways
  • 6.2 Rare Disease Market Attractiveness (by Test Type)
  • 6.3 Overview: Test Type
  • 6.4 Market Overview: Disease Type
  • 6.5 Market Value (by Genetic Test Type), 2017-2025
  • 6.6 Market Value (by General Lab Tests), 2017-2025
  • 6.7 Market Value (by Imaging Test Type), 2017-2025
  • 6.8 Market Value (by Other Tests), 2017-2025

7 Global Rare Disease Diagnostics Market (by Trait)

  • 7.1 Key Takeaways
  • 7.2 Rare Disease Market Attractiveness (by Trait Type)
  • 7.3 Overview: Trait Type
  • 7.4 Market Overview: Trait Type
  • 7.5 Market Value (by Inherited Trait Type), 2017-2025
  • 7.6 Market Value (by Acquired Trait Type), 2017-2025

8 Global Rare Disease Diagnostics Market (by Age Group)

  • 8.1 Key Takeaways
  • 8.2 Rare Disease Market Attractiveness (by Age Group)
  • 8.3 Overview: Age Group
  • 8.4 Market Overview: Age Group
  • 8.5 Market Value (by Children Age Group), 2017-2025
  • 8.6 Market Value (by Adult Age Group), 2017-2025

9 Global Rare Disease Diagnostics Market (by End User)

  • 9.1 Key Takeaways
  • 9.2 Rare Disease Market Attractiveness (by End User)
  • 9.3 Market Overview: End User
  • 9.4 Market Value (by Hospital Laboratories), 2017-2025
  • 9.5 Market Value (by Diagnostic laboratories), 2017-2025
  • 9.6 Market Value (by Genetic Testing Laboratories), 2017-2025
  • 9.7 Market Value (by Cancer Research Laboratories), 2017-2025
  • 9.8 Market Value (by Other End User), 2017-2025

10 Global Rare Disease Diagnostics Market (by Region)

  • 10.1 Market Overview (by Region)
  • 10.2 Global Rare Disease Diagnostics Market (by Region)
  • 10.3 Market Value (by Region)

11 North America Rare Disease Diagnostics Market

  • 11.1 Market Overview (by Country)
  • 11.2 North America: Impact of Market Drivers and Market Restraints
  • 11.3 Market Value (by Country)
  • 11.4 Market Value: U.S. Rare Disease Diagnostics Market, 2017-2025
  • 11.5 Market Value: Canada Rare Disease Diagnostics Market, 2017-2025

12 Europe Rare Disease Diagnostics Market

  • 12.1 Market Overview (by Country)
  • 12.2 Europe: Impact of Market Drivers and Market Restraints
  • 12.3 Market Value (by Country)
  • 12.4 Market Value: U.K Rare Disease Diagnostics Market, 2017-2025
  • 12.5 Market Value: Germany Rare Disease Diagnostics Market, 2017-2025
  • 12.6 Market Value: France Rare Disease Diagnostics Market, 2017-2025
  • 12.7 Market Value: Russia Rare Disease Diagnostics Market, 2017-2025
  • 12.8 Market Value: Italy Rare Disease Diagnostics Market, 2017-2025
  • 12.9 Market Value: Spain Rare Disease Diagnostics Market, 2017-2025
  • 12.10 Market Value: Rest-of-Europe Rare Disease Diagnostics Market, 2017-2025

13 Latin America Rare Disease Diagnostics Market

  • 13.1 Market Overview (by Country)
  • 13.2 Latin America: Impact of Market Drivers and Market Restraints
  • 13.3 Market Value (by Country)
  • 13.4 Market Value: Brazil Rare Disease Diagnostics Market, 2017-2025
  • 13.5 Market Value: Mexico Rare Disease Diagnostics Market, 2017-2025
  • 13.6 Market Value: Rest-of-Latin America Rare Disease Diagnostics Market, 2017-2025

14 Asia Pacific Rare Disease Diagnostics Market

  • 14.1 Market Overview (by Country)
  • 14.2 Asia-Pacific: Impact of Market Drivers and Market Restraints
  • 14.3 Market Value (by Country)
  • 14.4 Market Value: China Rare Disease Diagnostics Market, 2017-2025
  • 14.5 Market Value: Japan Rare Disease Diagnostics Market, 2017-2025
  • 14.6 Market Value: India Rare Disease Diagnostics Market, 2017-2025
  • 14.7 Market Value: Australia Rare Disease Diagnostics Market, 2017-2025
  • 14.8 Market Value: Singapore Rare Disease Diagnostics Market, 2017-2025
  • 14.9 Market Value: Rest-of-Asia-Pacific Rare Disease Diagnostics Market, 2017-2025

15 MEA Rare Disease Diagnostics Market

  • 15.1 Market Overview (by Country)
  • 15.2 MEA: Impact of Market Drivers and Market Restraints
  • 15.3 Market Value (by Country)
  • 15.4 Market Value: GCC Country Rare Disease Diagnostics Market, 2017-2025
  • 15.5 Market Value: South Africa Rare Disease Diagnostics Market, 2017-2025
  • 15.6 Market Value: Rest-of-MEA Rare Disease Diagnostics Market, 2017-2025

16 Company Profiles

  • 16.1 23andMe, Inc.
    • 16.1.1 Company Overview
    • 16.1.2 Product Portfolio
    • 16.1.3 Recent Development
    • 16.1.4 SWOT Analysis
  • 16.2 3billion, Inc.
    • 16.2.1 Company Overview
    • 16.2.2 Product Portfolio
    • 16.2.3 Global Footprint
    • 16.2.4 Financial Overview
    • 16.2.5 Recent Development
    • 16.2.6 SWOT Analysis
  • 16.3 BGI
    • 16.3.1 Company Overview
    • 16.3.2 Product Portfolio
    • 16.3.3 Recent Development
    • 16.3.4 SWOT Analysis
  • 16.4 Centogene A.G.
    • 16.4.1 Company Overview
    • 16.4.2 Product Portfolio
    • 16.4.3 Global Footprint
    • 16.4.4 Recent Development
    • 16.4.5 SWOT Analysis
  • 16.5 Eurofins Scientific
    • 16.5.1 Company Overview
    • 16.5.2 Product Portfolio
    • 16.5.3 Global Footprint
    • 16.5.4 Financial Overview
    • 16.5.5 Net Revenue (by Business Segment)
    • 16.5.6 Recent Development
    • 16.5.7 SWOT Analysis
  • 16.6 GENEWIZ
    • 16.6.1 Company Overview
    • 16.6.2 Product Portfolio
    • 16.6.3 Recent Development
    • 16.6.4 SWOT Analysis
  • 16.7 Illumina Inc.
    • 16.7.1 Company Overview
    • 16.7.2 Product Portfolio
    • 16.7.3 Global Footprint
    • 16.7.4 Net Revenue (by Business Segment)
    • 16.7.5 Recent Development
    • 16.7.6 SWOT Analysis
  • 16.8 InDepth Genomics
  • 16.9 Laboratory Corporation of America
    • 16.9.1 Company Overview
    • 16.9.2 Product Portfolio
    • 16.9.3 Global Footprint
    • 16.9.4 Financial Overview
    • 16.9.5 Net Revenue (by Business Segment)
    • 16.9.6 Recent Development
    • 16.9.7 SWOT Analysis
  • 16.10 Partek, Inc.
    • 16.10.1 Company Overview
    • 16.10.2 Product Portfolio
    • 16.10.3 Recent Development
    • 16.10.4 SWOT Analysis
  • 16.11 PerkinElmer, Inc.
    • 16.11.1 Company Overview
    • 16.11.2 Product Portfolio
    • 16.11.3 Global Footprint
    • 16.11.4 Net Revenue (by Business Segment)
    • 16.11.5 Recent Development
    • 16.11.6 SWOT Analysis
  • 16.12 Personal Genome Diagnostics, Inc.
    • 16.12.1 Company Overview
    • 16.12.2 Product Portfolio
    • 16.12.3 Recent Development
    • 16.12.4 SWOT Analysis
  • 16.13 QIAGEN N.V.
    • 16.13.1 Company Overview
    • 16.13.2 Product Portfolio
    • 16.13.3 Global Footprint
    • 16.13.4 Net Revenue (by Business Segment)
    • 16.13.5 Recent Development
    • 16.13.6 SWOT Analysis
  • 16.14 Retrophin, Inc.
    • 16.14.1 Company Overview
    • 16.14.2 Product Portfolio
    • 16.14.3 Global Footprint
    • 16.14.4 Financial Overview
    • 16.14.5 Net Revenue (by Business Segment)
    • 16.14.6 Recent Development
    • 16.14.7 SWOT Analysis
  • 16.15 Strand Life Sciences Pvt Ltd.
    • 16.15.1 Company Overview
    • 16.15.2 Product Portfolio
    • 16.15.3 Global Footprint
    • 16.15.4 Recent Development
    • 16.15.5 SWOT Analysis

Report Scope

List of Tables

  • Table 1 List of web-based and computer-aided tools available to help in diagnosing and managing rare genetic diseases (1/2)
  • Table 2 Genetic Tests
  • Table 3 Rare Disease Policies
  • Table 4 Limitation to Diagnostic Devices or Tests
  • Table 5 Genetic Test: Service Providers
  • Table 6 Funding for Rare Disease Research
  • Table 7 List of Regulatory Bodies

List of Figures

  • Figure 1 Rare disease diagnostic evaluation steps
  • Figure 2 Problems/Challenges/Web-based Solutions
  • Figure 3 Rare Disease Diagnostics Market (by Disease Type), Incremental Opportunity (%)
  • Figure 4 Rare Disease Diagnostics Market Value, Billion
  • Figure 5 Market Share (by Disease Type), %, 2018
  • Figure 6 Rare Disease Diagnostics Market (Y-o-Y), 2017-2025
  • Figure 7 Market Share (by Test Type), %, 2018
  • Figure 8 Market Share (by Trait), %, 2018
  • Figure 9 Market Share (by Age), %, 2018
  • Figure 10 Market Share (by End User), %, 2018
  • Figure 11 Global Rare Disease Diagnostics Market Value (by Disease Type), $Billion
  • Figure 12 Global Rare Disease Diagnostics Market Value (by Test Type), $Billion
  • Figure 13 Global Rare Disease Diagnostics Market Value (by Trait Type), $Billion
  • Figure 14 Global Rare Disease Diagnostics Market Value (by Age Group Type), $Billion
  • Figure 15 Global Rare Disease Diagnostics Market Value (by End User), $Billion
  • Figure 16 Global Rare Disease Diagnostics Market Revenue, (By Hematology and Oncology), $Billion
  • Figure 17 Market Revenue (by Region), 2017, $Billion
  • Figure 18 Region with the Highest CAGR. %, 2018-2025
  • Figure 19 Product Manufacturer, Service Providers, Research Organization Collaborations
  • Figure 20 Global Rare Disease Diagnostics Market (by Region), $Billion
  • Figure 21 Global Rare Disease Diagnostics Market (by Disease Type)
  • Figure 22 Global Rare Disease Diagnostics Market (by Disease Type), 2025
  • Figure 23 Global Rare Disease Diagnostics Market (by Test Type), 2018
  • Figure 24 Global Rare Disease Diagnostics Market (by Test Type), 2025
  • Figure 25 Global Rare Disease Diagnostics Market (by Trait Type), 2018
  • Figure 26 Global Rare Disease Diagnostics Market (by Trait Type), 2025
  • Figure 27 Global Rare Disease Diagnostics Market (by Age Group), 2018
  • Figure 28 Global Rare Disease Diagnostics Market (by Age Group), 2025
  • Figure 29 Global Rare Disease Diagnostics Market (by End User), 2018
  • Figure 30 Global Rare Disease Diagnostics Market (by End User), 2025
  • Figure 31 Global Rare Disease Diagnostics Market (by Region), 2018
  • Figure 32 Global Rare Disease Diagnostics Market (by Region), 2025
  • Figure 33 Challenges in Getting to the Right Doctor
  • Figure 34 Rare Disease Prevalence across various countries
  • Figure 35 Partnerships and Coordinated Efforts of the Rare Diseases Community
  • Figure 36 Global Rare Disease Diagnostics Market, 2017-2025
  • Figure 37 Prevalence of Rare Disease
  • Figure 38 Approximate number of gene discoveries by method
  • Figure 39 Percentage of rare disease research in next five years
  • Figure 40 Increase in genetic test development for diseases, 2016
  • Figure 41 Full genome sequencing becomes affordable
  • Figure 42 Orphan Drug Approvals
  • Figure 43 Competitive Landscape (January 2014-February 2018)
  • Figure 44 Distribution of European registries by coverage
  • Figure 45 IRDiRC Member Evolution
  • Figure 46 Distribution of Funded Projects and Trials by Type of Research
  • Figure 47 Distribution of Research Projects by Medical Domain
  • Figure 48 Service Providers
  • Figure 49 Industry Insights (January 2014-February 2018)
  • Figure 50 NIH Funding On Rare Diseases ($Mn)
  • Figure 51 Orphan drug legislation timeline
  • Figure 52 Rare Disease Diagnostics Market Attractiveness (by Disease Type)
  • Figure 53 Rare Disease Diagnostics Market (by Disease Type)
  • Figure 54 Global Rare Disease Diagnostics Market (by Disease Type), 2017-2025
  • Figure 55 Global Rare Disease Diagnostics Market (by Gastroenterology Disease Type), 2017-2025
  • Figure 56 Global Rare Disease Diagnostics Market, ((by Endocrine and Metabolism Disorders Disease Type)) 2017-2025
  • Figure 57 Global Rare Disease Diagnostics Market (by Cardiovascular Disorders), 2017-2025
  • Figure 58 Global Rare Disease Diagnostics Market (by Neurology Disease Type), 2017-2025
  • Figure 59 Global Rare Disease Diagnostics Market (by Hematology and Oncology Disease Type), 2017-2025
  • Figure 60 Global Rare Disease Diagnostics Market (by Dermatology Disease Type), 2017-2025
  • Figure 61 Global Rare Disease Diagnostics Market (by Other therapeutic Areas), 2017-2025
  • Figure 62 Rare Disease Diagnostics Market Attractiveness (by Test Type)
  • Figure 63 Rare Disease Diagnostics Market (by Test Type)
  • Figure 64 Global Rare Disease Diagnostics Market (by Test Type), 2017-2025
  • Figure 65 Global Rare Disease Diagnostics Market (by Genetic Test Type), 2017-2025
  • Figure 66 Global Rare Disease Diagnostics Market (by General Lab Tests), 2017-2025
  • Figure 67 Global Rare Disease Diagnostics Market (by Imaging Test Type), 2017-2025
  • Figure 68 Global Rare Disease Diagnostics Market (by Others), 2017-2025
  • Figure 69 Rare Disease Diagnostics Market Attractiveness (by Trait Type)
  • Figure 70 Rare Disease Diagnostics Market (by Trait)
  • Figure 71 Global Rare Disease Diagnostics Market (by Trait), 2017-2025
  • Figure 72 Global Rare Disease Diagnostics Market (by Inherited Trait Type), 2017-2025
  • Figure 73 Global Rare Disease Diagnostics Market (by Acquired Trait Type), 2017-2025
  • Figure 74 Rare Disease Diagnostics Market Attractiveness (by Age Group)
  • Figure 75 Rare Disease Diagnostics Market (by Age Group)
  • Figure 76 Global Rare Disease Diagnostics Market (by Children), 2017-2025
  • Figure 77 Global Rare Disease Diagnostics Market (by Children Age Group), 2017-2015
  • Figure 78 Global Rare Disease Diagnostics Market (by Adults Age Group), 2017-2025
  • Figure 79 Rare Disease Diagnostics Market Attractiveness (by End User)
  • Figure 80 Global Rare Disease Diagnostics Market (by End User), 2017-2025
  • Figure 81 Global Rare Disease Diagnostics Market, by Hospital Laboratories, 2017-2025
  • Figure 82 Global Rare Disease Diagnostics Market by Diagnostic laboratories, 2017-2025
  • Figure 83 Global Rare Disease Diagnostics Market by Genetic Testing Laboratories, 2017-2025
  • Figure 84 Global Rare Disease Diagnostics Market (by Cancer Research Laboratories), 2017-2025
  • Figure 85 Global Rare Disease Diagnostics Market (by Other End User), 2017-2025
  • Figure 86 Absolute Dollar Opportunity (by Region)
  • Figure 87 Market Share: (by Region) 2018
  • Figure 88 Market Share: (by Region) 2025
  • Figure 89 Rare Disease Diagnostics Market Year-on-Year Growth
  • Figure 90 Global Rare Disease Diagnostics Market (by Region)
  • Figure 91 Global Rare Disease Diagnostics Market (by Region), 2017-2025
  • Figure 92 Market Value, $Billion
  • Figure 93 North America Rare Disease Diagnostics Market (by Country)
  • Figure 94 North America Rare Disease Diagnostics Market (by Country), 2017-2025
  • Figure 95 The U.S. Rare Disease Diagnostics Market, 2017-2025
  • Figure 96 Canada Rare Disease Diagnostics Market, 2017-2025
  • Figure 97 Europe Market Value, Billion
  • Figure 98 Europe Rare Disease Diagnostics Market Share (by Country)
  • Figure 99 Europe Rare Disease Diagnostics Market (by Country), 2017-2025
  • Figure 100 U.K Rare Disease Diagnostics Market, 2017-2025
  • Figure 101 Germany Rare Disease Diagnostics Market, 2017-2025
  • Figure 102 France Rare Disease Diagnostics Market, 2017-2025
  • Figure 103 Russia Rare Disease Diagnostics Market, 2017-2025
  • Figure 104 Italy Rare Disease Diagnostics Market, 2017-2025
  • Figure 105 Spain Rare Disease Diagnostics Market, 2017-2025
  • Figure 106 Rest-of-Europe Rare Disease Diagnostics Market, 2017-2025
  • Figure 107 Latin America Market Value, Billion
  • Figure 108 Latin America Rare Disease Diagnostics Market (by Country)
  • Figure 109 Latin America Rare Disease Diagnostics Market (by Country), 2017-2025
  • Figure 110 Brazil Rare Disease Diagnostics Market, 2017-2025
  • Figure 111 Mexico Rare Disease Diagnostics Market, 2017-2025
  • Figure 112 Rest-of-Latin America Rare Disease Diagnostics Market, 2017-2025
  • Figure 113 Market Value, Billion
  • Figure 114 Asia Pacific Rare Disease Diagnostics Market (by Country)
  • Figure 115 Asia Pacific Rare Disease Diagnostics Market (by Country), 2017-2025
  • Figure 116 China Rare Disease Diagnostics Market, 2017-2025
  • Figure 117 India Rare Disease Diagnostics Market, 2017-2025
  • Figure 118 Japan Rare Disease Diagnostics Market, 2017-2025
  • Figure 119 Australia Rare Disease Diagnostics Market, 2017-2025
  • Figure 120 Singapore Rare Disease Diagnostics Market, 2017-2025
  • Figure 121 Rest-of-Asia-Pacific Rare Disease Diagnostics Market, 2017-2025
  • Figure 122 MEA Market Value, Billion
  • Figure 123 MEA Rare Disease Diagnostics Market (by Country)
  • Figure 124 MEA Rare Disease Diagnostics Market (by Country), 2017-2025
  • Figure 125 GCC Countries Rare Disease Diagnostics Market, 2017-2025
  • Figure 126 South Africa Rare Disease Diagnostics Market, 2017-2025
  • Figure 127 Rest-of-MEA Rare Disease Diagnostics Market, 2017-2025